scholarly journals Gastroenteropancreatic neuroendocrine tumor of the accessory papilla of the duodenum: a case report

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Kosei Takagi ◽  
Yuzo Umeda ◽  
Ryuichi Yoshida ◽  
Kazuhiro Yoshida ◽  
Kazuya Yasui ◽  
...  
Keyword(s):  
Lymph Node ◽  
Neuroendocrine Tumor ◽  
Lymph Node Metastases ◽  
Treatment Strategy ◽  
Gastroenteropancreatic Neuroendocrine Tumors ◽  
Ki 67 ◽  
Invasive Approach ◽  
Robotic Pancreatoduodenectomy ◽  
Estimated Blood Loss ◽  
Node Metastases

Abstract Background Contrary to the increasing incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), GEP-NETs of the accessory papilla of the duodenum are extremely rare. Furthermore, there have been no recommendations regarding the treatment strategy for GEP-NETs of the accessory papilla of the duodenum. We present a case of GEP-NET of the accessory papilla of the duodenum successfully treated with robotic pancreatoduodenectomy. Case presentation A case of a 70-year-old complaining of no symptoms was diagnosed with GEP-NET of the accessory papilla of the duodenum. A 8-mm tumor was located at the submucosal layer with a biopsy demonstrating a neuroendocrine tumor grade 1. The patient underwent robotic pancreatoduodenectomy as curative resection for the tumor. The total operative time was 406 min with an estimated blood loss of 150 mL. The histological examination revealed a well-differentiated neuroendocrine tumor with low Ki-67 index (< 1%). In the posterior areas of the pancreas, the lymph node metastases were detected. The patient was followed up for 6 months with no recurrence postoperatively. Conclusions Considering the potential risks of the lymph node metastases, the standard treatment strategy for GEP-NETs of the accessory papilla of the duodenum should be radical resection with pancreatoduodenectomy. Minimally invasive approach can be the alternative to the conventional open surgery.

scholarly journals ERα and ERβ expression in correlation with Ki-67, Bcl-2 and Bak in primary tumors and lymph node metastases of breast cancer: The effect of pre-operative chemotherapy

2010 ◽  
Vol 1 (6) ◽  
pp. 1067-1071 ◽  
Author(s):  
LUIZA KANCZUGA-KODA ◽  
MARIUSZ KODA ◽  
JAKUB TOMASZEWSKI ◽  
KATARZYNA JARZABEK ◽  
JOANNA LOTOWSKA ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastases ◽  
Ki 67 ◽  
Primary Tumors ◽  
Node Metastases

Predictors of sentinel lymph node metastases in breast cancer-radioactivity and Ki-67

The Breast ◽  
2016 ◽  
Vol 30 ◽  
pp. 87-91 ◽  
Author(s):  
Fabinshy Thangarajah ◽  
Wolfram Malter ◽  
Stefanie Hamacher ◽  
Matthias Schmidt ◽  
Stefan Krämer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Lymph Node Metastases ◽  
Ki 67 ◽  
Node Metastases

scholarly journals A 9mm Rectal Neuroendocrine Tumor G1 with Lateral Lymph Node Metastases

2018 ◽  
Vol 51 (1) ◽  
pp. 72-80
Author(s):  
Takaya Kobatake ◽  
Ryoji Ochiai ◽  
Naruyuki Kobayashi ◽  
Yoshihiro Mikuriya ◽  
Shinji Hato ◽  
...  
Keyword(s):  
Lymph Node ◽  
Neuroendocrine Tumor ◽  
Lymph Node Metastases ◽  
Lateral Lymph Node ◽  
Node Metastases ◽  
Rectal Neuroendocrine Tumor

Expression of ERα, ERβ and Ki-67 in primary tumors and lymph node metastases in breast cancer

2004 ◽  
Author(s):  
Mariusz Koda ◽  
Stanislaw Sulkowski ◽  
Luiza Kanczuga-Koda ◽  
Eva Surmacz ◽  
Mariola Sulkowska
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastases ◽  
Ki 67 ◽  
Primary Tumors ◽  
Node Metastases

scholarly journals The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer

2007 ◽  
Author(s):  
Mariusz Koda ◽  
Mariola Sulkowska ◽  
Luiza Kanczuga-Koda ◽  
Jakub Tomaszewski ◽  
Waldemar Kucharczuk ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastases ◽  
Ki 67 ◽  
Primary Tumors ◽  
Node Metastases

Cytokeratin 7 negative invasive breast carcinoma: clinicopathological and immunohistochemical analysis of 14 cases with clinical follow-up

2015 ◽  
Vol 68 (6) ◽  
pp. 484-487 ◽  
Author(s):  
Neda A Moatamed ◽  
Annie Wu ◽  
Khaled Sarah ◽  
Sophia K Apple
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastases ◽  
Proliferation Index ◽  
Axillary Lymph ◽  
Cytokeratin 7 ◽  
Ki 67 ◽  
Her 2 ◽  
Node Metastases ◽  
Work Up

Cytokeratin 7 (CK 7) negative breast tumours are reported to occur rarely. We studied 14 CK 7 negative cases of primary invasive ductal carcinoma (IDC) detected during sentinel lymph node metastases work-up and immunohistochemistry panel in the work-up of metastatic carcinoma of unknown origin. Axillary lymph node metastases were present in seven patients (50%). Oestrogen receptor (ER) was strongly positive in all cases: progesterone receptor in 78%, Her-2/neu in 7% and high proliferation index with Ki-67 >20% was seen in 71% of the cases.Metastatic and/or recurrence were found in 8 of 14 patients (57%) with the mean clinical follow-up of 55 months. Metastatic sites include multiple bones, brain, spinal cord, liver, pancreas, ovary, lung, lymph node other than ipsilateral axillary and skin. 12 of 14 patients received adjuvant chemotherapy. All 14 patients received hormonal therapy and radiation therapy. Morphologically, IDC with neuroendocrine features was noted in 57%. Synaptophysin stain was positive in 57% and chromogranin was positive in 21% of the cases. In conclusion, these CK 7 negative breast carcinomas were ER positive, mostly Her-2/neu negative, had high Ki-67 and frequently showed neuroendocrine differentiation. More than half of these cases had a poor outcome.

Correlation between NEN bone metastasis performance and tumor proliferation: 112 cases of [68Ga]Ga-DOTA-TATE results analysis

2021 ◽  
Author(s):  
Qing Xie ◽  
Ming Lu ◽  
Shizhen Zhai ◽  
Rui Guo ◽  
Changzhi Du ◽  
...  
Keyword(s):  
Lymph Node ◽  
Bone Metastasis ◽  
Negative Correlation ◽  
Lymph Node Metastases ◽  
Final Analysis ◽  
Proliferation Index ◽  
Neuroendocrine Neoplasm ◽  
Ki 67 ◽  
Normal Bone ◽  
Node Metastases

Purpose: To analyze neuroendocrine neoplasm (NEN) bone metastasis (BM) and Gallium-68 (68Ga)-DOTA-TATE performance and to explore their correlation with the immunohistochemical proliferation index (Ki-67). Procedures: A total of 112 patients with BMs were screened from 1082 NEN patients who underwent [68Ga]Ga-DOTA-TATE imaging. All patients had pathological results, and BMs were affirmed by clinical/imaging follow-up of and/or histopathology. The maximum standard uptake value (SUVmax) ratio of BM to normal bone determined for each patient was used in the final analysis. Results: The incidence rate of BMs in NENs was 10.35%. BMs occurred in the spine (75%), pelvis (72.3%), ribs (58%), clavicles and scapulae (41.1%), limbs (37.5%) and skull (28.6%). Most cases were associated with liver metastases (70.5%) and lymph node metastases (65.2%) simultaneously. The SUVmax ratio of G3b (median ratio=3.77, Ki-67>55%) was significantly lower than that of G1 (11.43, Ki-67≤2%) and G2a (11.15, 3%≤Ki-67≤10%) separately P<0.05), while no differences were found for the G2b (8.5, 11%≤Ki-67≤55%) and G3a (6.64, Ki-67>55%) groups. In the total patients there was a significant negative correlation between the SUVmax ratio of BMs to normal bone and Ki-67 (r=-0.267, P<0.01). According to the changes in bone density on computed tomography (CT) scans, the cases were divided into four groups: osteogenesis, osteolysis, no change and a mixed group (median Ki-67: 6.5%, 15%, 12%, and 22.5%). The Ki-67 values were significantly different between the osteogenesis group and the other groups (P<0.05). Conclusion: BM is present in 10.35 % of NEN patients, and most have simultaneous liver and/or lymph node metastases. The occurrence of osteogenesis indicates relativity good differentiation and there is a negative correlation between SUVmax ratio of BMs and NEN proliferation.

Sign in / Sign up

Export Citation Format

Share Document